These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.
    Author: Bathaix F, Marion D, Cuinet M, Maillard E, Zoulim F, Mornex F, Merle P.
    Journal: Gastroenterol Clin Biol; 2010; 34(4-5):314-8. PubMed ID: 20207091.
    Abstract:
    Sorafenib has recently been approved as the gold standard therapy for advanced BCLC-C hepatocellular carcinomas. Although significant improvement of survival rates was shown, objective tumor response rates remained low following RECIST criteria in phases 2 and 3 studies. We report the rare case of a patient with a large hepatocellular carcinoma tumor invading suprahepatic veins in which sorafenib led to a very significant regression by about 90% of the tumor bulk, thus allowing at sterilizing the residual tumor tissue by subsequent combination of transarterial intrahepatic chemoembolization and high dose radiotherapy.
    [Abstract] [Full Text] [Related] [New Search]